The abstract is read at the publisher; the summary is JClub's.
In adults with obesity, once-weekly retatrutide produced greater weight loss than placebo over 80 weeks, reaching -25.0% with 12 mg versus -3.9%.
- Why it matters: Weight reduction is a key unmet need in obesity, and improvements in joint pain and sleep-disordered breathing could broaden clinical benefit beyond scale weight.
- What they did: In a phase 3 randomized, double-blind trial, adults without diabetes received retatrutide 4 mg, 9 mg, or 12 mg or placebo for 80 weeks, with primary outcomes assessed in knee osteoarthritis (n=574) and obstructive sleep apnea (n=243) subgroups.
- The result: Retatrutide also reduced WOMAC pain and apnea-hypopnea events versus placebo (both P<0.001), with gastrointestinal adverse events most common.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.